RSV vaccines - risk, competition and a big prize, eventually


26-02-2019

This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines, releases a brand new commercial assessment of Respiratory Syncytial Virus (RSV) vaccines. The field is one of the most active in the vaccine industry with many competitors investigating numerous approaches. But will the first mover reap the biggest reward?

Human Respiratory Syncytial Virus (RSV) is one of the most common viruses to infect children worldwide and is now increasingly recognised as an important pathogen in adults, especially the elderly. Globally each year, there are over 33m episodes of RSV-associated acute lower respiratory infection in children younger than five years of age resulting at least 3.2m hospital admissions and 59,600 in hospital deaths (2015 estimation, Shi T et al., 2017). In children below five years, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. 

There is no specific treatment for RSV infection and for those children who require hospitalization (~1-2% of healthy), supportive therapy is still the mainstay of care. Palivizumab (anti-RSV monoclonal, Synagis®) has been FDA approved since 1998 for the prophylaxis of specific subsets of premature infants but has several limitations.

Despite serious setbacks in the late 1960s with a formalin-inactivated RSV vaccine, the RSV vaccine development field is now one of the most active in the industry. Major companies such as Pfizer, GSK Biologicals, Janssen NV and smaller biotech’s e.g. Novavax have a range of vaccine approaches in active clinical development targeting all the recognized target populations. Newer long-acting monoclonal antibodies such as MEDI8897 (MedImmune) and MK1654 (Merck & Co) are also being pursued.

This MarketVIEW product is a comprehensive Executive Presentation (~210 slides, .pdf) and MS-Excel forecast model which investigate the interplay and commercial potential of four RSV vaccine profiles in all relevant target groups (e.g. maternal, infant, adult “at risk” and elderly) to 2035. 52 countries and sub-regions are included in the model with expected public and private sector vaccination being indicated.  A methodology has been created whereby country specific roll-out is forecasted according to specific local factors and RSV transmission patterns which may in turn influence RSV program adoption. The report contains a thorough review of current disease background/epidemiology/CE and vaccinology with an emphasis on structural-based antigen engineering. An analysis of the R&D competitive environment (including long acting mAbs) is also provided. This product is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV vaccine opportunity.

For more information, please contact info@vaczine-analytics.com or visit www.vaczine-analytics.com

Image Credit: Picsea @picsea

VacZine Analytics, a world-leading supplier of vaccine-related commercial analyses, is a trading division of Assay Advantage Ltd (UK Company No: 5807728, UK VAT: 883584084)

 

VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)